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Abstract
Purpose: The role of computed tomography (CT) scan, as a promising prognostic imaging modality in cystic fibrosis 
(CF), has been widely investigated, focusing on parenchymal abnormalities. The aim of the present study was to 
evaluate the diagnostic performance of thoracic vascular parameters on CT to detect pulmonary hypertension (PH).
Material and methods: CF patients who contemporaneously underwent CT and echocardiography were retrospectively 
enrolled. Baseline characteristics in addition to pulmonary artery diameter (PAD) and pulmonary to aortic (PA/A) 
ratio were compared between cohorts with and without PH, based on the results of echocardiography separately in 
paediatric patients (< 18) and adults (≥ 18).
Results: Of a total 119 CF patients, 39 (32.8%) had PH (paediatric: 23/78, 29.5%, adult: 16/41, 39%). In paediatric CF 
patients, mean age, HCo3, PCo2, and pulmonary artery diameter (PAD) were significantly higher in the PH group 
compared to the non-PH group. Mean pulmo however, only PAD remained as the independent predictor of PH based 
on multivariate analysis (overall: 22.86 mm [±3.86] vs. 18.43 mm [±4.72], p = 0.005, paediatric patients: 22.63 mm 
[±4.4] vs. 17.10 mm [±4.64], p = 0.03). Using a cut off of 19.25 mm, the diagnostic performance of PAD to detect PH 
was found to be as follows: sensitivity = 82%, specificity = 70%, and accuracy = 73.1%. No significant difference was 
demonstrated in PAD between PH and non-PH groups in adults with CF (23.19 [±3.60] vs. 21.34 [±3.49], p = 0.7).
Conclusions: In CF patients, PAD revealed an age-dependent performance to detect PH. PAD can be applied to predict 
pulmonary hypertension in paediatric CF patients and may be recommended to be routinely measured on follow-up 
chest CT scan in childhood CF.
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Introduction
Pulmonary hypertension (PH) is commonly encountered 
in advanced cystic fibrosis (CF) and is associated with 
a poor prognosis. The results of a recent study demon-
strated that, regardless of the severity, the hazard ratio of 
pulmonary hypertension and related impact on mortality 
is significantly higher in CF patients than that of other 
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lung diseases [1]. Prompt in to a multidisciplinary ther-
apeutic approach, including drug treatment, nutritional 
support and respiratory rehabilitation, early detection of 
PH in CF patients may hence contribute to prevent or 
slow disease progression, improving quality of life and 
probably survival. Echocardiography, as the most sensi-
tive non-invasive screening tool for PH, may not perform 
as a reliable tool in advanced lung parenchymal diseases, 
which frequently occurred in CF patients [2,3]. In ad-
dition, pulmonary function test may not correlate well 
with the course and severity of pulmonary parenchymal 
and vascular disease [4,5]. Right-sided heart catheteri-
sation as the gold standard for diagnosis of PH with the 
capability of providing additional valuable information 
for patient stratification and treatment strategies is not 
frequently indicated in CF patients and may be asso-
ciated with some major complications [6]. There is an 
increasing body of evidence suggesting a potential role 
for CT-measured vascular parameters to identify pulmo-
nary hypertension. The results of a recent meta-analysis 
on 2134 cases from 20 publications revealed that pul-
monary artery diameter and pulmonary-to-aorta ratio 
had a modest sensitivity (79%) and specificity (81%) 
with a good overall accuracy to detect pulmonary hy-
pertension and may play a complementary role in the 
diagnostic approach to PH [7]. Providing details about 
both vascular and parenchymal components, CT may be 
considered as the imaging modality of choice for disease 
monitoring in progressive lung diseases; however, evi-
dence about the diagnostic and prognostic implication 
of CT vascular metric in CF patients is scarce. A recent 
study revealed that the PA/A ratio has a strong correla-
tion with acute respiratory exacerbation and also with 
cystic fibrosis transmembrane conductance regulator 
(CFTR) dysfunction in adults with CF and hence may 
provide valuable prognostic information in this cohort 
[8]. In addition, few studies are available investigating 
normal values of thoracic vasculature in the paediatric 
population [9] as well as any relation between vascular 
parameters and PH. The aim of the present study was 
to investigate the relationship between chest CT vascular 
parameters and pulmonary artery systolic pressure in CF 
patients, as well as their performance characteristics to 
detect PH, separately in paediatric and adult groups.
Material and methods
Patients
In this retrospective chart review study, all patients with 
proven diagnosis of CF admitted to the paediatric wards 
of Masih Daneshvari Hospital between 2012 and 2016 
were consecutively included. Patients contemporaneously 
investigated by CT scan and echocardiography with 
a maximum interval of two weeks were then selected. 
Cardiopulmonary co-morbidity and PH with aetiologies 
other than CF and aortic aneurysm/dilatation were con-
sidered as exclusion criteria. The study was approved by 
the Institutional Review Board, and the need for informed 
consent was waived. Demographic and anthropometric 
characteristics including age, sex, body mass index (BMI), 
and arterial blood gas indices including pH, PCO2, HCO3, 
pulmonary function test including FEV1 (forced expirato-
ry volume in 1 second; predicted), FEV1/FVC (forced vital 
capacity), and pulmonary artery systolic pressure based 
on echocardiography were extract from the patients’ files 
and recorded separately for each case. No PFT records 
were available for patients under the age of six years. 
Based on pulmonary artery systolic pressure (PASP), pa-
tients were then divided into two groups: 1) PH group, 
defined as patients with PASP ≥ 25 mmHg and 2) non-
PH group, defined as patients with PASP < 25 mmHg. 
Regarding the potential effect of age on the pulmonary 
artery diameter [10], the study cohort were subsequent-
ly categorised into paediatric (≤ 18 years old) and adult 
CF (> 18 years) groups, and all the parameters were then 
compared between the PH and non-PH group in each age 
group, using the same cut-off.
CT acquisition
CT scan was performed using a spiral CT unit (Siemens 
SOMATOM Emotion Series, Siemens Erlangen, Germa-
ny). All patients were imaged in the supine position, in in-
spiratory phases from lung apex to below the costophrenic 
angles, according to the standard acquisition protocol in 
adults and paediatric patients, as appropriate: 80-100 mA, 
110 kVp, 1-1.4 pitch, and 0.5-second rotation time. CT 
scans were reconstructed at section widths of 1 mm and 
intervals of 20 mm. 
CT vascular metrics
The widest short-axis diameter of the main pulmonary 
artery was measured on the axial section at the level of the 
main pulmonary artery bifurcation in mediastinal win-
dow setting (window width 400, window centre 30) on 
expiratory phase images. The widest short-axis diameter 
of ascending aorta was then measured on an axial section 
at the same level. The main pulmonary artery diameter 
(PA) to ascending aorta (A) (PA/A) ratio was then calcu-
lated. The measures were performed blinded to the hae-
modynamic results.
Echocardiography
Colour Doppler echocardiography was performed us-
ing Vivid 7 dimension; Mann healthcare, GE. PASP was 
calculated as the sum of the peak trans-tricuspid systolic 
pressure gradient and right atrium pressure, using modi-
fied Bernoulli equation. PASP ≥ 25 mmHg was considered 
as PH.
 Pulmonary artery diameter in CF pulmonary pressure
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Statistical analysis
Normally distributed data were analysed using parametric 
tests. Continuous (age, BMI, HCO3, PCO2, FEV1, FEV1/
FVC, PASP, PAD, PA/A ratio) and categorical (gender) 
variables were described as mean (±SD) and frequency 
(per cent), respectively. The significance of difference for 
each variable between two groups was tested using inde-
pendent t-test, Mann-Whitney U test, and chi-square, as 
appropriate. Correlation between vascular and haemod-
ynamic parameters was analysed using Pearson’s corre-
lation test. Variables with significant different based on 
univariate analysis were further analysed in a logistic re-
gression model. Diagnostic performance of pulmonary 
artery diameter and PA/A ratio and appropriate cut-off 
were calculated using receiver operating characteristic 
(ROC) analysis. A p value < 0.05 was considered as a sta-
tistically significant difference. Data were analysed using 
SPSS ver. 23. 
Results 
Of a total 119 patients with CF, 74 (62.2%) were male 
and 45 (38.7%) were female (p = 0.008), with mean age 
of 14.87 ±6.4 years (age range: 3-33 years). Mean age did 
not demonstrate a significant difference between male and 
female (14.4 vs. 15.62, p = 0.3). 
In this study the mean PAD was 19.88 mm. The mean 
diameter of the pulmonary artery was greater in adults 
with CF compared to paediatric patients (22.06 vs. 18.73, 
p = 0.000). 
Regarding haemodynamic parameters, mean PASP 
was measured as 24.39 mmHg. Based on a PASP cut-
off of 25 mmHg, 39 patients (32.8%) had increased pul-
monary hypertension (mean PASP = 32.8 mmHg), and 
80 (67.2%) showed normal pulmonary systolic arterial 
pressure (mean PASP = 20.05 mmHg). The frequency 
of PH and mean PASP did not show a significant differ-
ence between paediatric and adults with CF in this study 
(29.5% vs. 39%, p = 0.29 and 24.08 vs. 24.97, p = 0.18) 
Among demographic and anthropometric character-
istics, mean age was significantly higher in the PH group 
(16.94 vs. 13.85 years old, p = 0.015). The PH paediatric 
group had also a significantly higher mean age compared 
to the non-PH paediatric group (14.26 vs. 10.44 years old, 
p = 0.001); however, such a difference was not demon-
strated between PH and non-PH groups in adult CF pa-
tients (22 vs. 20.81, p = 0.22). 
Among arterial blood gas indices, mean PCo2 and 
HCo3 were found to have significantly higher values in the 
PH group compared to the non-PH cohort (47.98 [±9.03] 
vs. 44.11 [±11.70], p = 0.011 and 29.89 [±4.06] vs. 27.31 
[±6.27], p = 0.003, respectively). The same results were ob-
tained for paediatric CF patients (45.83 [±11.43] vs. 43.5 
[±11.76], p = 0.03 and 38.92 [±4.27] and 31.42 [±3.14], 
p = 0.003, respectively). There was a trend toward a higher 
mean HCo3 in the CF adult PH group than in the non-
PH cohort, although it was not statistically significant 
(p = 0.08) (Table 1). 
There was a borderline statistical significant difference 
in FEV1 between the PH and non-PH group (p = 0.064). 
While no difference was found in pulmonary function 
test values between the paediatric PH and non-PH group, 
adult PH patients had a significantly higher value of FEV1/
FVC compared to the non-PH adult cohort (p = 0.04). 
Mean pulmonary arterial diameter and pulmo-
nary-to-aortic (PA/A) ratio were significantly greater 
in the PH group than in those with normal pulmonary 
pressure (22.86 vs. 18.42, p = 0.000 and 1.03 vs. 0.95, 
p = 0.002). In the paediatric group with CF, CT vascular 
metrics were also significantly higher in the PH group 
than in the non-PH group, although such a difference 
was not demonstrated in adult CF patients. Table 2 sum-
marises the CT-measured vascular parameters, based on 
a PASP cut-off of 25 mmHg, as the discriminator of PH 
from non-PH groups. 
There was a statistically significant correlation be-
tween haemodynamic (PSAP) and vascular param-
eters (paediatric patients – PAD: [R] = 0.59, p = 0.000, 
PA/A ratio: [R] = 0.47, p = 0.00; adults – PAD: [R] = 0.51, 
p = 0.006, PA/A ratio: [R] = 0.45, p = 0.023). In paediatric 
patients, the correlation between PSAP and age was also 
significant ([R] = 0.49, p = 0.000). Pulmonary systolic ar-
tery pressure demonstrated a weaker inverse correlation 
with HCo3 ([R] = –0.43, p = 0.003) and PCo2 ([R] = –0.34, 
p = 0.029) in children. 
Figure 1 demonstrates the area under the ROC curve 
of pulmonary artery diameter as 0.81 (CI: 0.68-0.85, 
p = 0.000) and for the PA/A ratio as 0.73 (CI: 0.57-0.78, 
p = 0.002). Using cut-off of 19.25 mm, the sensitivity and 
specificity of PAD for identification of PH were 82% and 
70%, respectively. At a cut-off value of 0.94, the PA/A ratio 
demonstrated a sensitivity of 83% and specificity of 55%. 
The results were similar for total CF and cohort and pae-
diatric CF patients. 
Variables with a significant correlation with PSAP 
(age, PCo2, HCo3, PAD, PA/A ratio) based on univariate 
analysis were further analysed by multiple regression test, 
which revealed PAD as the only independent predictor 
of PH in total CF patients (p = 0.006) and in paediatric 
CF patients (p = 0.033). In adults groups, no independent 
relationship was found between pulmonary artery hyper-
tension and CT-measured vascular metrics. 
Discussion
The current study provided new insight into the age-de-
pendent performance of CT-measured PAD to predict PH 
in CF patients. PAD may serve as a reliable tool to identify 
PH in paediatric patients with CF; however, no significant 
association was found between the level of PASP and pul-
monary artery diameter in adults. 
Mehrdad Bakhshayeshkaram, Farahnaz Aghahosseini, Fatemeh Vaezi et al.  
e404 © Pol J Radiol 2018; 83: e401-e406
Table 1. Baseline characteristics in patients with and without pulmonary hypertension
Characteristics Overall
(n = 119)
PSAP 
< 25 mmHg
(n = 39, 32.8%)
PSAP 
≥ 25 mmHg
(n = 83, 67.2%)
P value 
(univariate 
analysis)
P value
(multiple
logistic 
regression)
Demographics Age (yr)
Overall 14.86 (±6.4) 13.85 (±7.08) 16.94 (±4.04) 0.003 0.97
Pediatrics 11.36 (±4.68) 10.14 (±4.74) 14.26 (±2.78) 0.000 0.3
Adults 21.53 (±3.03) 22 (±3.58) 20.81 (±1.76) 0.22
Gender
Overall
Male 74 (62.2%) 54 (72.97%) 20 (27.02%) 0.08
Female 45 (37.8%) 26 (57.78%) 19 (42.22%)
Pediatrics
Male 49 (62.82%) 38 (77.55%) 11 (22.45%) 0.07
Female 29 (31.18%) 17 (58.62%) 12 (41.39%)
Adults 0.62
Male 25 (60.97%) 16 (64%) 9 (36%)
Female 16 (39.02%) 7 (43.75%) 9 (56.25%)
Anthropometrics BMI
Overall
< 20 106 (84.1%) 72 (67.92%) 34 (32.08%) 0.6
20-25 13 (10.4%) 8 (61.53%) 5 (38.46%)
Pediatrics
< 20 72 (92.3%) 51(70.8%) 21(29.2%) 0.8
20-25 6 (7.7%) 4 (66.7%) 2 (33.3%)
Adults
< 20 34 (82.9%) 21 (61.8%) 13 (38.2%) 0.8
20-25 7 (17.1%) 4 (57.1%) 3 (42.9%)
Arterial blood gas indices Overall
pH 7.39 (±0.06) 7.4 (±0.06) 7.39 (±0.06) 0.89
PCo2 (mmHg) 45.37 (±11.01) 44.11 (±11.7) 47.99 (±9.03) 0.011 0.37
HCo3 (mmol/l) 28.16 (±5.76) 27.31 (±6.29) 29.89 (±4.05) 0.003 0.15
Pediatrics
pH 7.39 (±0.057) 7.4 (±0.06) 7.34 (±0.05) 0.66
PCo2 (mmHg) 44.18 (±11.64) 43.5 (±11.76) 45.83 (±11.43) 0.03 0.64
HCo3 (mmol/l) 33.63 (±35.96) 34.42 (±32.91) 38.93 (±42.72) 0.003 0.5
Adults
pH 7.39 (±0.07) 7.34 (±0.06) 7.39 (±0.08) 0.82 
PCo2 (mmHg) 45.91 (±12.2) 44.08 (±13.46) 48.78 (±4.64) 0.32
HCo3 (mmol/l) 34.18 (±3.8) 27.09 (±6.7) 45.26 (±5.97) 0.08
Pulmonary function test Overall
FEV1 53.47 (±25.69) 57.14 (±26.26) 47.57 (±23.84) 0.064
FEV1/FVC 97.12 (±14.73) 94.14 (±15.98) 98.79 (±12.33) 0.61
Pediatric
FEV1 56.91 (±28.23) 55.28 (±31.86) 46.3 (±26.11) 0.29
FEV1/FVC 97.03 (±16.33) 97.33 (±17.96) 96.47 (±13.2) 0.56
Adults
FEV1 48.63 (±20.97) 49.32 (±21.02) 47.36 (±21.52) 0.55
FEV1/FVC 97.26 (±11.95) 94.16 (±12.00) 102.12 (±10.44) 0.04
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Table 2. Pulmonary hemodynamic and vascular metrics in patients with and without pulmonary hypertension
Characteristics Overall
(n = 119)
PSAP < 25 
mmHg
(n = 83, 67.2%)
PSAP ≥ 25 
mmHg
(n = 39, 32.8%)
P value 
(univariate 
analysis)
P value
(multiple logistic 
regression)
Pulmonary systolic pressure (mmHg)
Overall 24.39 (±8.85) 20.05 (±7.93) 33.30 (±10.98) 0.00
Pediatrics 24.08 (±8.46) 19.94 (±7.3) 34 (±10.69) 0.00
Adults 24.97 (±9.32) 20.28 (±8.9) 32.31 (±11.66) 0.000
Pulmonary artery diameter (mm)
Overall 19.88 (±4.91) 18.43 (±4.72) 22.86 (±3.86) 0.000 0.005
Pediatrics 18.73 (±5.13) 17.10 (±4.64) 22.63 (±4.4) 0.000 0.03
Adults 22.06 (±3.61) 21.34 (±3.49) 23.19 (±3.60) 0.7
PA/A
Overall 0.98 (±0.12) 0.95 (±0.11) 1.03 (±0.13) 0.002 0.79
Pediatrics 0.99 (±0.12) 0.97 (±0.11) 1.05 (±0.13) 0.001 0.77
Adults 0.96 (±0.13) 0.94 (±0.12) 1.00 (±0.14) 0.125
Few studies are available investigating various aspects 
of PH in CF. It has been shown that PH is frequently seen 
in advanced CF (57%) [10]. In the present study, the fre-
quency of PH was found to be 32.8%. This difference may 
be at least partly due to the lower prevalence of advanced 
CF in the current study (2.5%). 
Pulmonary hypertension is a pathophysiological con-
dition caused by a variety of diseases mediated via differ-
ent underlying anatomical and physiological mechanisms. 
In chronic obstructive pulmonary disease (COPD), re-
cent studies have demonstrated that a direct toxic effect 
of tobacco on the intima proceed vascular remodelling 
via abnormal production of the mediators controlling 
vasodilation and vasoconstriction and also abnormal in-
timal cell proliferation [11,12]; however, in CF patients, 
vascular remodelling is strongly influenced by the alveolar 
hypoxia as well as a chronic systemic inflammatory con-
dition [13,14]. Augmentation index (AIx), as a significant 
predictor of arterial stiffness with a potential association 
with systemic inflammation, has been demonstrated to 
have higher values in the adult CF population, indicat-
ing an accelerated vascular ageing process in this cohort 
[14]. Despite an independent relationship in paediatric 
CF, the present study failed to demonstrate any striking 
correlation between pulmonary artery diameter and PH 
in adult CF. Taking this into consideration, one possible 
explanation is the well-established premature vascular ag-
ing and advanced arterial stiffness in adult CF compared 
to the paediatric group, preventing a linear relationship 
between pulmonary artery pressure and pulmonary artery 
diameter. 
Most researches demonstrated that pulmonary hae-
modynamic indices are independent of lung function 
status in CF patients [13], which is in accordance with 
the results obtained in the present study. Such results pro-
vided evidence for the major limitation of PFT to be solely 
applied for disease monitoring in CF patients, and they 
support the potential value of CT-measured thoracic vas-
cular diameter as a complementary test to PFT for com-
prehensive disease monitoring in paediatric CF patients. 
Several reports revealed a significant correlation be-
tween obesity and PH. One study demonstrated that 72% 
of subjects with BMI > 30 kg/m2 showed haemodynamic 
changes in pulmonary circulation, including venous hy-
pertension and alveolar capillary haemangiomatosis, in-
dicating of an underlying PH [15]. Another study demon-
strated that the frequency of obesity was significantly 
higher in patients with PH than in those with normal pul-
monary pressure [16]. The same result was also observed 
in COPD patients with pulmonary hypertension – mean 
BMI was significantly higher in patients with PH (28 vs. 25, 
 p = 0.04) [17]. However, the current study failed to pro-
vide any association between BMI and pulmonary systolic 
arterial pressure as well as CT vascular metrics. This dis-
crepancy could be explained by the confounding effect of 
underlying malnutrition status most frequently seen in CF 
patients as a result of pulmonary function disturbance and 
gastrointestinal complications including pancreatic insuffi-
ciency, steatorrhoea, hepatic steatosis, and biliary fibrosis. 
The present study has some major drawbacks. Retro-
spective data collection from a single CF centre may limit 
the validity of results to the CF patient population. How-
ever, it should be noted that Masih Daneshvari Hospital, 
as a tertiary referral centre for CF with a comprehensive 
CF registry, provides a wide coverage of CF patients in 
Iran. The impact of CT vascular metrics to predict PH on 
clinical outcome needs to be further investigated. None 
of the patients were candidates for right-sided heart cath-
eterisation, and hence the exact value of haemodynamic 
parameters measured by gold standard were not available; 
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however, the current results may be less influenced by the 
selection bias in the studies performed on RVH candidate 
cohorts. Associated pulmonary parenchymal involvement 
as a major determinant of survival with a potential impact 
on pulmonary arterial systolic pressure was not evaluated 
in this study. Small subsets of patients in age groups and 
limited age range of adult CF (up to 33 years old) should 
be considered as the important consideration for the pres-
ent results. 
In conclusion, the current study provided evidence for 
the age-dependent performance of CT-based pulmonary 
artery diameter, as an easily obtainable measurement, to 
predict PH. PAD correlates well with PH in paediatric 
patients with CF, and this relationship is independent 
of age, lung function test, and arterial blood gas indices. 
In this regard, CT-measured thoracic vascular diameter 
may be recommended as a complementary test to pulmo-
nary function test for monitoring of disease progression 
in childhood CF. However, the added value of CT-based 
follow-up approach in paediatric CF should be further 
validated by large-scale prospective survival studies con-
sidering excess radiation exposure.
Conflict of interest
The authors declare that they have no conflict of interest.
References
1. Hayes Jr D, Tobias JD, Mansour HM, et al. Pulmonary hypertension 
in cystic fibrosis with advanced lung disease. Am J Respir Crit Care 
Med 2014; 190: 898-905. 
2. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assess-
ment of pulmonary hypertension in patients with advanced lung 
disease. Am J Respir Crit Care Med 2003; 167: 735-740. 
3. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echo-
cardiography in the hemodynamic assessment of pulmonary hyper-
tension. Am J Respir Crit Care Med 2009; 179: 615-621. 
4. Helbich TH, Heinz-Peer G, Eichler I, et al. Cystic fibrosis: CT assess-
ment of lung involvement in children and adults. Radiology 1999; 
213: 537-544. 
5. Fraser KL, Tullis DE, Sasson Z, et al. Pulmonary hypertension and 
cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 
1999; 115: 1321-1328. 
6. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmo-
nary arterial hypertension: ACCP evidence-based clinical practice 
guidelines. Chest 2004; 126 (1 Suppl): 78S-92S. 
7. Ussavarungsi K, Whitlock JP, Lundy TA, et al. The significance of 
pulmonary artery size in pulmonary hypertension. Diseases 2014; 
2: 243-259. 
8. Akay HO, Ozmen CA, Bayrak AH, et al. Diameters of normal tho-
racic vascular structures in pediatric patients. Surg Radiol Anat 
2009; 31: 801-807. 
9. Compton GL, Florence J, MacDonald C, et al. Main pulmonary 
artery–to–ascending aorta diameter ratio in healthy children on 
MDCT. Am J Roentgenol 2015; 205: 1322-1325. 
10. Hayes D, Higgins RS, Kirkby S, et al. Impact of pulmonary hyper-
tension on survival in patients with cystic fibrosis undergoing lung 
transplantation: an analysis of the UNOS registry. J Cyst Fibros 
2014; 13: 416-423. 
11. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic 
obstructive pulmonary disease: current theories of pathogenesis and 
their implications for treatment. Thorax 2005; 60: 605-609. 
12. Zakynthinos E, Daniil Z, Papanikolaou J, Makris D. Pulmonary hy-
pertension in COPD: pathophysiology and therapeutic targets. Curr 
Drug Targets 2011; 12: 501-513. 
13. Fraser KL, Tullis DE, Sasson Z, et al. Pulmonary hypertension and 
cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 
1999; 115: 1321-1328. 
14. Hull JH, Garrod R, Ho TB, et al. Increased augmentation index in 
patients with cystic fibrosis. Eur Respir J 2009; 34: 1322-1328. 
15. Haque AK, Gadre S, Taylor J, et al. Pulmonary and cardiovascu-
lar complications of obesity: an autopsy study of 76 obese subjects. 
Arch Pathol Lab Med 2008; 132: 1397-1404. 
16. Chan AL, Juarez MM, Shelton DK, et al. Novel computed tomo-
graphic chest metrics to detect pulmonary hypertension. BMC Med 
Imaging 2011; 11: 7. 
17. Shin S, King CS, Brown AW, et al. Pulmonary artery size as a pre-
dictor of pulmonary hypertension and outcomes in patients with 
chronic obstructive pulmonary disease. Respir Med 2014; 108: 
1626-1632.
